Published in Br J Cancer on January 01, 1994
The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem (1987) 5.79
Differences in the carbohydrate structures of neural cell-adhesion molecules from adult and embryonic chicken brains. J Biol Chem (1982) 3.83
Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun (1977) 3.17
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40
Tissue- and developmental stage-specific forms of a neural cell surface antigen linked to differences in glycosylation of a common polypeptide. EMBO J (1982) 1.92
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res (1992) 1.73
Ricin transport in brefeldin A-treated cells: correlation between Golgi structure and toxic effect. J Cell Biol (1991) 1.64
Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res (1990) 1.46
Recombinant toxins for cancer treatment. Science (1991) 1.36
Preparation of antibody-toxin conjugates. Methods Enzymol (1985) 1.34
A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci U S A (1987) 1.21
Lung cancer biology. Semin Oncol (1988) 1.18
Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. Br J Cancer (1990) 1.17
Antigens of lung cancer: results of the second international workshop on lung cancer antigens. J Natl Cancer Inst (1991) 1.07
An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res (1991) 1.01
The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry (1991) 0.95
Immunotoxins--entry into cells and mechanisms of action. Immunol Today (1989) 0.92
Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins. J Biol Chem (1987) 0.90
Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer. Br J Cancer Suppl (1991) 0.90
Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res (1993) 0.90
Antitumor activity of a thioether-linked immunotoxin: OVB3-PE. Bioconjug Chem (1991) 0.88
An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. Int J Cancer (1989) 0.87
Potentiation of antitumor immunotoxins by liposomal monensin. J Natl Cancer Inst (1993) 0.85
Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology. Cancer Res (1991) 0.83
Action of a CD24-specific deglycosylated ricin-A-chain immunotoxin in conventional and novel models of small-cell-lung-cancer xenograft. Int J Cancer (1993) 0.80
Presence of neural cell adhesion molecule on human embryonic and brain tumours. Biochem Soc Trans (1990) 0.79
Human melanoma cell lines showing striking inherent differences in sensitivity to immunotoxins containing holotoxins. J Natl Cancer Inst (1986) 0.78
Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer. Cancer Immunol Immunother (1992) 0.78
Pseudomonas exotoxin: recombinant conjugates as therapeutic agents. Biochem Soc Trans (1992) 0.77
Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule. Clin Exp Immunol (1992) 0.77
Immunotoxins of Pseudomonas exotoxin A (PE): effect of linkage on conjugate yield, potency, selectivity and toxicity. Mol Immunol (1990) 0.77
Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer. Int J Cancer (1993) 0.77
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res (2000) 2.32
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol (2007) 1.85
Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst (1997) 1.78
Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. J Clin Oncol (1985) 1.64
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol (1997) 1.61
An ankyrin-like protein with transmembrane domains is specifically lost after oncogenic transformation of human fibroblasts. J Biol Chem (1999) 1.58
CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res (1992) 1.57
Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. Br J Cancer (1989) 1.57
Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol (1989) 1.51
Tumor-associated membrane sialoglycoprotein on human small cell lung carcinoma identified by the IgG2a monoclonal antibody SWA20. Cancer Res (1988) 1.44
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol (2001) 1.35
High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res (1999) 1.32
Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer (1992) 1.20
Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. Br J Cancer (1990) 1.17
Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett (2007) 1.17
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol (2004) 1.17
Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med (1999) 1.16
Characterization of an epithelial and a tumor-associated human small cell lung carcinoma glycoprotein antigen. Cancer Res (1987) 1.15
Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small-cell carcinoma and squamous-cell carcinomas. Int J Cancer (1985) 1.14
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J (2011) 1.14
Expression of the small cell carcinoma antigens of cluster-5 and cluster-5A in primary lung tumours. Br J Cancer (1989) 1.13
Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl (1994) 1.11
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol (2005) 1.10
Cytotoxic murine monoclonal antibody LAM8 with specificity for human small cell carcinoma of the lung. Cancer Res (1986) 1.09
An amplified assay for thiols based on reactivation of papain. Anal Biochem (1993) 1.09
Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer (1998) 1.08
5'-Nucleotidases in rat heart. Evidence for the occurrence of two soluble enzymes with different substrate specificities. Biochem J (1988) 1.08
An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res (1991) 1.01
Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem (2001) 0.98
The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies. Br J Cancer (1994) 0.95
Mouse sperm antigens that participate in fertilization. I. Inhibition of sperm fusion with the egg plasma membrane using monoclonal antibodies. Biol Reprod (1985) 0.92
Imaging and therapy of small cell carcinoma xenografts using 131I-labeled monoclonal antibody SWA11. Cancer Res (1990) 0.92
A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res (2000) 0.92
Monoclonal anti-idiotypic antibody mimicking a tumor-associated sialoglycoprotein antigen induces humoral immune response against human small-cell lung carcinoma. Int J Cancer (1989) 0.91
Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int J Cancer (2000) 0.91
Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer. Br J Cancer Suppl (1991) 0.90
Cytoskeleton-associated proteins: their role as cellular integrators in the neoplastic process. Crit Rev Oncol Hematol (1985) 0.90
T-cell derived cytokines co-stimulate proliferation of CD40-activated germinal centre as well as follicular lymphoma cells. Hematol Oncol (1997) 0.89
Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody. Br J Cancer (1991) 0.88
Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol (1984) 0.87
Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells. Cancer Immunol Immunother (2001) 0.87
An autocrine mitogenic activity produced by a pleural human mesothelioma cell line. Int J Cancer (1992) 0.87
Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma. Int J Cancer (1988) 0.87
Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Biochem Biophys Res Commun (1996) 0.87
Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer (2000) 0.86
The small cell lung cancer antigen cluster-4 and the leukocyte antigen CD24 are allelic isoforms of the same gene (CD24) on chromosome band 6q21. Cytogenet Cell Genet (1995) 0.86
Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol (1997) 0.86
Characterization of human matrilin-3 (MATN3). Genomics (1998) 0.86
Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline. Clin Exp Immunol (1993) 0.85
[Automatic interpretation of electronystagmograms (author's transl)]. Biomed Tech (Berl) (1975) 0.85
Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res (2001) 0.85
Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst (2001) 0.85
Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. J Clin Invest (1985) 0.85
DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells. J Neurooncol (2005) 0.85
Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells. Br J Haematol (2001) 0.85
Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol (2005) 0.84
Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. Int J Cancer (1999) 0.84
Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer (1990) 0.84
Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. Br J Cancer (1994) 0.84
A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol Immunother (1997) 0.83
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia. Ann Oncol (2005) 0.83
Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer Suppl (1994) 0.83
Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines. Br J Cancer (1992) 0.83
The 5'-flanking region of human CD24 gene has cell-type-specific promoter activity in small-cell lung cancer. Int J Cancer (1998) 0.83
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. Br J Cancer (1991) 0.82
Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Ther (1996) 0.81
Assay for thiols based on reactivation of papain. Methods Enzymol (1995) 0.81
Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes. Cancer Res (1993) 0.81
Action of a CD24-specific deglycosylated ricin-A-chain immunotoxin in conventional and novel models of small-cell-lung-cancer xenograft. Int J Cancer (1993) 0.80
Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie (2003) 0.80
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer (1999) 0.80
Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma. Cancer Biother Radiopharm (2001) 0.80
Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer. Br J Cancer (1993) 0.80
Novel approaches to the treatment of small-cell lung cancer. Cell Mol Life Sci (1999) 0.80
46,XX/46,XY chimerism in a phenotypically normal man. Hum Genet (1983) 0.80
Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer. Br J Cancer (1992) 0.80
Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study. Oncology (2000) 0.79
Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung. Cancer Res (1985) 0.79